Does Medicare cover Entyvio?

Entyvio is the kind of medication that makes two things happen at once: your gastroenterologist gets hopeful,
and your wallet starts doing breathing exercises. The good news? Medicare often does cover Entyvio.
The not-as-fun news? Which part of Medicare pays depends on how you get Entyvio
(IV infusion vs. self-injection) and what coverage you have (Original Medicare vs. Medicare Advantage).

This guide synthesizes real, current information from Medicare and federal guidance, major nonprofit Medicare resources,
and official drug labeling and manufacturer materialsthen translates it into plain English, with fewer acronyms per paragraph
than a government memo (you’re welcome).

The quick answer

• Entyvio IV infusions are typically covered under Medicare Part B when given in a doctor’s office,
  infusion center, or hospital outpatient department (assuming it’s medically necessary).
• Entyvio “pen” (subcutaneous self-injection) is typically covered under Medicare Part D (or the drug benefit
  portion of a Medicare Advantage plan) because it’s generally treated as an outpatient prescription you administer yourself.
• Your out-of-pocket cost can range from “manageable” to “why is my printer also out of ink?” depending on
  whether you have supplemental coverage (like Medigap), your plan’s cost-sharing rules, and where you receive treatment.

What is Entyvio, and how is it given?

Entyvio (vedolizumab) is a biologic used to treat moderate to severe ulcerative colitis and
Crohn’s disease. It’s often prescribed when other treatments haven’t worked well enough or weren’t tolerated.
One reason doctors like it: it’s designed to be gut-focused, targeting immune-cell trafficking to the GI tract.

Two ways to receive Entyvio

• IV infusion (provider-administered): A healthcare professional gives Entyvio through an IV. The infusion itself
  is commonly described as taking about 30 minutes. After the starter doses, many patients continue on a maintenance schedule
  (often every 8 weeks, though clinicians can adjust based on response).
• Subcutaneous injection (the “pen,” self-administered): In the U.S., the subcutaneous form is approved for
  maintenance therapy after induction with IV Entyvio. This means you don’t usually start with the pen right out of the gate.

Why Medicare coverage depends on “how it’s administered”

Medicare draws a bright-ish line between:
drugs administered by a healthcare professional in a clinical setting (often Part B) and
outpatient prescription drugs you take yourself (often Part D).
Entyvio can live in either neighborhood depending on whether it’s infused or injected at home.

When Part B is the usual payer

Part B commonly covers drugs and biologics that are infused or injected by a clinician
in settings like a physician office or hospital outpatient departmentespecially drugs that aren’t “usually self-administered.”
That description fits Entyvio IV pretty well.

When Part D is the usual payer

Part D (prescription drug coverage) is generally where Medicare puts medications you pick up through a pharmacy
and administer yourself. That’s typically how the Entyvio pen is handled.
Coverage is plan-specific: your plan’s formulary (drug list) determines whether it’s covered and what tier it’s on.

So… does Medicare cover Entyvio IV?

In many cases, yesMedicare Part B often covers Entyvio IV when it’s medically necessary and administered in an
approved setting. But Medicare doesn’t automatically cover “anything your doctor likes.” Coverage is tied to medical necessity,
diagnosis, and proper billing.

Common settings where Entyvio IV is billed to Part B

• Physician office infusion suite
• Independent infusion center
• Hospital outpatient department (often covered, but sometimes costs more out-of-pocket due to facility copays)

Billing codes you may hear (and why you should care)

Most people never want to hear the phrase “HCPCS code” unless it’s followed by “and you don’t have to do anything.”
Still, knowing the basics can help you sanity-check coverage calls.

• J3380 is commonly used for vedolizumab (Entyvio) under HCPCS, typically billed per milligram.
• Facilities may also bill separate codes for infusion administration, supplies, and nursing time.
  (This matters because your cost-sharing may apply to the drug and the administration.)

Does Medicare cover the Entyvio pen (self-injection)?

Often yesbut usually through Part D (or the drug benefit of a Medicare Advantage plan), not Part B.
Here’s the key point: Part D coverage is not uniform across Medicare. Two neighbors can both have Part D,
and one plan may cover the pen on a preferred specialty tier while the other may require a prior authorization (or prefer a different drug).

Why “maintenance after IV induction” matters

The subcutaneous version is approved for maintenance therapy after IV induction. In real life, that can affect coverage rules,
because plans may require documentation that you:

• have an appropriate diagnosis (Crohn’s disease or ulcerative colitis),
• completed induction with IV Entyvio (or otherwise meet criteria), and
• continue to meet medical-necessity requirements.

What you’ll pay: Part B costs vs. Part D costs

If Entyvio is covered under Part B (typical for IV)

Under Original Medicare, after you meet the Part B deductible, you generally pay
20% coinsurance of the Medicare-approved amount for covered Part B services and drugs.
If you receive Entyvio IV in a hospital outpatient department, you may also owe a separate
hospital copayment for outpatient servicessometimes making hospital-based infusions pricier than office-based infusions.

Real-world example (simplified): If the Medicare-approved amount for the drug + administration were $8,000,
your 20% coinsurance could be $1,600 for that visit. That number can change significantly depending on site of care,
Medicare’s allowed amounts, and whether facility fees apply.

How people lower Part B out-of-pocket costs:

• Medigap (Medicare Supplement) can cover some or most of the 20% coinsurance, depending on the plan.
• Some people with limited income may qualify for Medicare Savings Programs or other assistance.
  (Eligibility is income- and state-dependent.)

If Entyvio is covered under Part D (typical for the pen)

With Part D, what you pay depends on your plan’s:
deductible, tier placement, coinsurance/copays,
and whether the medication is treated as a specialty drug.
The important modern twist: starting in 2025, Medicare implemented a major Part D redesign that includes an
annual out-of-pocket cap (indexed after 2025), and beneficiaries can also choose a
Prescription Payment Plan option to spread out-of-pocket costs across monthly payments during the year.

Translation: even if a specialty drug hits hard in January, you may have options to make that hit feel less like a financial jump-scare.
It doesn’t necessarily make the drug cheaperbut it can make it more predictable.

Original Medicare vs. Medicare Advantage: the same drug, different rules

Original Medicare (Part A + Part B, plus optional Part D)

With Original Medicare, the “division of labor” is usually straightforward:
IV Entyvio → Part B, Entyvio pen → Part D.
Your biggest variables are supplemental insurance (Medigap), site of care, and Part D plan design.

Medicare Advantage (Part C)

Medicare Advantage plans must cover what Original Medicare covers, but they can structure costs differently and use
networks, prior authorization, step therapy, and preferred infusion providers.
In practice, that means:

• Your GI doctor and infusion center may need to be in-network.
• You may have a flat copay per infusion or a coinsurance percentage.
• Plan rules may strongly influence whether you infuse in a hospital outpatient department or a standalone infusion center.

Prior authorization, step therapy, and “prove it” paperwork

Whether you’re using Part B (infusion) or Part D (pen), it’s common for insurers to ask for documentation before approving a high-cost biologic.
This can include:

• Diagnosis confirmation (Crohn’s disease or ulcerative colitis, severity, clinical notes)
• Prior treatment history (what you tried, what failed, what wasn’t tolerated)
• Dosing schedule and planned setting of care
• Continuation criteria (evidence the drug is working over time)

If you’re denied, you typically have appeal rights. The fastest wins often happen when your doctor’s office submits
a clean, complete packet the first timebecause nothing delays care like the phrase: “We didn’t receive the fax.”

How to check your coverage (without losing your entire afternoon)

Step 1: Identify which form you’re getting

• IV infusion (clinic-administered) is usually a Part B question.
• Pen injection (self-administered) is usually a Part D formulary question.

Step 2: Ask the right coverage question

When you call Medicare/your plan, don’t ask only “Do you cover Entyvio?” Ask:

• “Is Entyvio IV covered under Part B for my diagnosis, and what is my coinsurance in my planned setting?”
• “Is the Entyvio pen on my Part D formulary, what tier is it, and what restrictions apply (PA, quantity limits)?”
• “Do I pay differently if I infuse in a hospital outpatient department versus an independent infusion center?”

Step 3: Get help from your doctor’s office (seriously)

GI clinics that prescribe biologics usually have staff who run benefits investigations all day.
Ask them to check coverage and estimate patient responsibility using:

• the drug billing code (often J3380 for vedolizumab),
• your plan details, and
• your intended site of care.

Cost-saving options people often overlook

1) Choosing the right site of care

If your plan allows it, getting infusions in a physician office or standalone infusion center can sometimes be less expensive than
a hospital outpatient department due to facility charges. This is not universalbut it’s common enough to be worth checking.

2) Supplemental coverage (Medigap) for Part B coinsurance

If you’re on Original Medicare and you need ongoing Part B infusions, a Medigap policy can be the difference between
“okay” and “I’m learning the term ‘coinsurance’ against my will.”

3) The Medicare Prescription Payment Plan (Part D)

If you use the Entyvio pen under Part D, look at the Prescription Payment Plan option that spreads out-of-pocket costs across the year.
It won’t magically reduce the plan-negotiated price, but it can keep your monthly budget from getting body-slammed early in the year.

4) Manufacturer programs and the Medicare reality check

Many brand-name drugs offer copay cards for commercially insured patients. But if you have Medicare (including Medicare Advantage),
those copay programs typically can’t be used. That’s not Entyvio being mean; it’s how federal program rules work.
Some people explore independent charitable foundations for help when available, but funding comes and goesso treat it like concert tickets:
if you see it, don’t assume it’ll still be there tomorrow.

FAQ

Is Entyvio always covered if my doctor prescribes it?

Not automatically. Medicare coverage generally requires medical necessity and proper documentation.
Plans may require prior authorization or evidence that other treatments were tried first.

Will Medicare cover Entyvio for both ulcerative colitis and Crohn’s disease?

Entyvio is FDA-approved for adults with moderate to severe ulcerative colitis and Crohn’s disease.
Coverage typically aligns with approved uses, but plans can still require documentation and may apply utilization management.

Is the Entyvio pen cheaper than infusions under Medicare?

Not necessarily. The pen often routes through Part D rules, while infusions often route through Part B rules.
Which is “cheaper” depends on your specific coverage (Medigap, Part D plan design, Medicare Advantage cost-sharing)
and where you receive care.

What’s the single most helpful thing I can do before starting Entyvio?

Ask your GI clinic’s billing or prior-authorization team to run a benefits investigation and give you an estimate
for both the drug and the administration costs. Then compare settings of care if your plan allows it.

Conclusion

YesMedicare often covers Entyvio, but the “how” matters as much as the “yes.”
If you receive Entyvio IV in a clinical setting, it’s commonly covered under Part B,
with typical cost-sharing around 20% unless you have supplemental coverage.
If you use the Entyvio pen, it’s commonly handled under Part D, where coverage and costs depend on
your plan’s formulary and specialty-drug rulesthough modern Part D protections (including an out-of-pocket cap and a payment-spreading option)
can help make costs more predictable.

Your best move is practical, not magical: confirm which form you’re using, ask about the site of care, and lean on your GI clinic’s insurance team.
Your colon deserves calmand your budget deserves fewer surprises.

Experiences: what navigating “Medicare + Entyvio” can feel like (realistic scenarios)

The word “experiences” is tricky here, because everyone’s Medicare setup is differentand no two phone calls with an insurance plan
have ever been the same (if they were, hold times would be shorter and unicorns would run the call center).
Instead of pretending there’s one universal story, here are a few composite, true-to-life scenarios that reflect what
many people run into when they’re trying to answer the question: “Does Medicare cover Entyvio?”

Scenario 1: Original Medicare + Medigap = fewer financial jump-scares

Barbara, 71, starts Entyvio IV for ulcerative colitis. Her GI office schedules infusions at an independent infusion center.
The clinic bills Medicare Part B for the drug and administration, and Barbara sees the Medicare-approved amounts on her statements.
Here’s the part that makes her exhale: she also has a Medigap plan that covers most (or all) of the Part B coinsurance.
So instead of facing a big 20% share every visit, she’s mostly focused on the usual premiums and staying consistent with treatment.

What she learns quickly is that the site of care matters. A hospital outpatient department would have been convenient,
but the office explains that hospital-based infusions can add facility-related copays in addition to the 20% coinsurance.
Barbara doesn’t become a billing expertshe just becomes billing-aware enough to ask one smart question before every schedule change:
“If we switch locations, does my cost change?”

Scenario 2: Original Medicare without supplemental coverage = the 20% reality

Marcus, 67, has Crohn’s disease and Original Medicare but no Medigap policy. His doctor recommends Entyvio IV.
Coverage isn’t the problemPart B can cover it when it’s medically necessary. The challenge is the coinsurance.
When Marcus asks his clinic for an estimate, he realizes that “20% of a biologic” is not a cute little math problem;
it’s a budget event.

Marcus and the clinic work through options: confirming the lowest-cost in-network infusion setting, checking whether he qualifies
for any assistance programs, and planning for predictability (because surprises are only fun in birthday parties and mystery novels).
The biggest “experience lesson” here isn’t medicalit’s administrative: you can often reduce stress by asking for a written estimate
and re-checking it at the start of each calendar year, when deductibles and plan cost-sharing can reset.

Scenario 3: Medicare Advantage = coverage yes, but with plan rules attached

Denise, 73, enrolls in a Medicare Advantage plan that includes drug coverage. Her plan covers Entyvio,
but the approval process involves prior authorization. The first request gets delayed because the plan wants documentation
that other therapies were tried first and notes confirming disease severity. Denise’s clinic resubmits with a more complete packet,
and approval comes through.

Then comes the second twist: the plan prefers a specific infusion provider and has different cost-sharing depending on
whether she infuses at a hospital outpatient department or a standalone infusion center. Denise’s “experience takeaway”
is that Advantage plans can be totally workablebut you have to play by the plan’s rules:
use in-network providers, get authorizations in advance, and ask about site-of-care costs before scheduling.

Scenario 4: Switching from IV to the pen = a Part D-style budgeting puzzle

Omar, 69, does well on Entyvio IV and later considers switching to the Entyvio pen for maintenance.
The convenience is real: fewer appointments and more flexibility. But the payment pathway changes.
Now, instead of Part B-style billing for an infusion visit, the pen is treated like a Part D medication.
That means formulary tiers, specialty-drug rules, and different cost-sharing logic.

Omar’s plan covers the pen with prior authorization, but the first fill is expensive early in the year.
The option that helps most is not a secret discountit’s a planning tool: he chooses the Medicare Prescription Payment Plan option
offered by his coverage, which spreads out-of-pocket costs more evenly across the year. The “experience lesson” is that
the pen may feel medically simple, but financially it’s worth doing a quick benefits check first, so convenience doesn’t come with
an avoidable budget surprise.

SEO tags (JSON)